Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

News

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings

Digest more
 · 19h · on MSN
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month’s supply of Novo Nordisk’s semaglutide pen products for $499 through GoodRx.

Continue reading

 · 2d · on MSN
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.
The Pharma Letter · 1d
GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy
ConsumerAffairs
56m

GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
1d

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...
1d

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval

Novo said cash-paying Americans can now buy Ozempic for $499 per month through various channels including its official ...
2d

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy